<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756622</url>
  </required_header>
  <id_info>
    <org_study_id>1078-20</org_study_id>
    <nct_id>NCT04756622</nct_id>
  </id_info>
  <brief_title>N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.</brief_title>
  <official_title>Efficacy and Safety of N-acetyl Cysteine for the Prevention of Oral Mucositis After High-dose Chemotherapy and Autologous Hematopoietic Cell Transplantation: a Phase III, Randomized, Open Label, Multi-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>moshe yeshurun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral mucositis (OM) is a major source of morbidity in patients undergoing hematopoietic cell&#xD;
      transplantation (HCT). N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic&#xD;
      agent or antidote of acetaminophen overdose hepatotoxicity. we intend to explore the safety&#xD;
      and efficacy of NAC in the prevention of OM after high-dose chemotherapy and autologous HCT&#xD;
      in a phase III, randomized, open label and multi-center study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, randomized, open label and multi-center study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with grade 3-4 OM</measure>
    <time_frame>day 14</time_frame>
    <description>Proportion of patients with grade 3-4 OM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with grade 1-4 OM</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with grade 1-4 OM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from transplantation to first hospital discharge</measure>
    <time_frame>30 days</time_frame>
    <description>Time from transplantation to first hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>day 50</time_frame>
    <description>Non-relapse mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Mucositis</condition>
  <condition>Transplant-Related Disorder</condition>
  <arm_group>
    <arm_group_label>N acetyl cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAC dissolved in water at a dose of 600 mg three times per day from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N acetyl cysteine</intervention_name>
    <description>N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.</description>
    <arm_group_label>N acetyl cysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with multiple myeloma and lymphoma in partial response and complete&#xD;
             remission.&#xD;
&#xD;
          -  Undergoing high-dose chemotherapy with autologous transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Known sensitivity to NAC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moshe Yeshurun, MD</last_name>
    <phone>0526015543</phone>
    <email>moshe.yeshurun@gmail.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>moshe yeshurun</investigator_full_name>
    <investigator_title>Head Bone Marrow UNit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

